Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
MWN-AI** Summary
Galecto, Inc. (NASDAQ: GLTO), a Boston-based biopharmaceutical company, has announced its plans for an underwritten public offering that includes both shares of common stock and Series C non-voting convertible preferred stock. The issuance, solely offered by Galecto, aims to raise funds for the advancement of its antibody programs, specifically targeting blood cancers. Each Series C share can convert into 1,000 shares of common stock, subject to certain beneficial ownership limits.
The company has also granted underwriters a 30-day option to purchase additional shares. This public offering is contingent on market conditions, and there is no guarantee regarding its completion or the terms involved. Galecto intends to utilize the proceeds from the offering, along with its existing cash resources, for essential preclinical studies and clinical trials, as well as for manufacturing, working capital, and overall corporate purposes.
The offering is being managed by Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities, with a registration statement filed with the SEC on February 10, 2026, allowing the issuance of these securities. Interested parties can obtain the preliminary prospectus through the aforementioned financial institutions.
As a clinical-stage biotechnology firm, Galecto specializes in developing innovative therapies for hematological cancers, including its promising pipeline focused on mutant calreticulin-driven conditions and tailored treatments for acute myeloid leukemia.
The announcement comes with cautionary notes about various risks and uncertainties tied to market conditions and the anticipated proceeds, which may differ from projections. The company underscores that the forward-looking statements are based on current assumptions, and there are no assurances that the desired outcomes will be achieved.
MWN-AI** Analysis
Galecto, Inc.'s proposed underwritten public offering of common stock and Series C non-voting convertible preferred stock represents a pivotal move as the company seeks to bolster its pipeline of innovative therapeutics aimed at treating hematological cancers. Investors should approach this announcement with a nuanced understanding of both potential opportunities and risks.
On one hand, this offering poses an opportunity for Galecto to strengthen its financial foundation, which is crucial for advancing its promising therapies, such as GB3226, a first-in-class treatment for acute myeloid leukemia. Notably, the ability of preferred stockholders to convert their shares into a significant volume of common stock could attract various investors, indicating a possible bullish sentiment on the long-term growth prospects of the company.
However, investors should remain cautious. The public offering is subject to market conditions, raising valid concerns about dilution of existing shares and the overall sentiment regarding the biotechnology sector. The significant reliance on capital markets for research and development expenses may expose Galecto to volatility in funding, especially in a climate where investors may prioritize profitability over speculative investments.
Additionally, the references to forward-looking statements underscore inherent uncertainties in biopharmaceutical development. With numerous external factors influencing clinical outcomes and regulatory approvals, there's the potential for divergence from expectations, which could affect stock performance.
In summary, while the public offering may present a financing strategy that fuels growth in Galecto’s pipeline, investors should weigh these prospects against market conditions and the company's capacity to deliver on its ambitious goals. A careful evaluation of the convertible preferred stock’s implications and an analysis of Galecto’s clinical progress and market dynamics will be crucial steps for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series C preferred stock will be convertible into 1,000 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series C preferred stock. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Galecto intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series C preferred stock, together with its cash and cash equivalents, for preclinical studies, clinical trials, and manufacturing in support of our antibody programs, as well as for additional research and development activities, working capital, and general corporate purposes.
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.
An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on February 10, 2026. This offering will be made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A copy of the preliminary prospectus and the accompanying prospectus relating to the offering may be obtained, when available, from: Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; or email: Prospectus_Department@Jefferies.com); Leerink Partners LLC (Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109; telephone: 800-808-7425 ext. 6105; or email: syndicate@leerink.com); Evercore Group L.L.C. (Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; telephone: 888-474-0200; or email: ecm.prospectus@evercore.com); or Guggenheim Securities, LLC (Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017; telephone: 212-518-9544; or email: GSEquityProspectusDelivery@guggenheimpartners.com).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding Galecto’s expectations regarding the proposed offering, including the timing, size, structure and completion of the proposed offering on the anticipated terms; the anticipated use of the net proceeds from the offering; the grant to the underwriters of the option to purchase additional shares; and express or implied statements relating to the Company’s expectations, hopes, beliefs, intentions or strategies regarding the future of its assets, pipeline and business. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, market conditions that may affect the timing, terms or conditions of the proposed underwritten public offering, the Company’s successful completion of the proposed underwritten public offering, the satisfaction of customary closing conditions related to the proposed underwritten public offering and those uncertainties and factors described under the headings “Risk Factors,” “Cautionary Information Regarding Forward-Looking Statements” or “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
FAQ**
What specific preclinical studies and clinical trials does Galecto Inc. (GLTO) plan to fund with the proceeds from the underwritten public offering, and how might these impact their pipeline development?
How does Galecto Inc. (GLTO) expect the introduction of the Series C non-voting convertible preferred stock to influence investor interest and the company's funding strategy?
Given the risks mentioned, what contingency plans does Galecto Inc. (GLTO) have in place to address potential market fluctuations that might affect the public offering?
What milestones does Galecto Inc. (GLTO) aim to achieve in its antibody programs following the completion of this public offering to create value for its shareholders?
**MWN-AI FAQ is based on asking OpenAI questions about Galecto Inc. (NASDAQ: GLTO).
NASDAQ: GLTO
GLTO Trading
-8.08% G/L:
$27.75 Last:
51,514 Volume:
$28.31 Open:
